04-20

2023

HealZen Therapeutics and Neushen Therapeutics Have Reached a Licensing Agreement

The two companies jointly announced their cooperation on the central nervous system (CNS) disease pipeline project. According to the terms of the agreement, Neushen will obtain global exclusive development rights, registration and commercialization rights for the project, involving indications such as epilepsy and emotional disorders. Based on this collaboration, HealZen Therapeutics will receive an upfront payment and R&D milestone payments.

04-17

2023

HZ-Q1070 Gave an Oral Presentation at the 2023 AACR Annual Meeting

HealZen Therapeutics and Dr. Jia Li's team from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences presented preclinical data of novel BTK degrader HZ-Q1070 for the first time in an oral presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

01-30

2023

HZ-A-018 Capsule Got Approval to Conduct Clinical Trials for Treating Relapsing Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

HealZen Therapeutics has recently announced that the self-developed innovative drug, HZ-A-018 capsule, a Bruton's tyrosine kinase (BTK) inhibitor, has been granted approval by the National Medical Products Administration (NMPA) to conduct clinical trials for relapsing multiple sclerosis (RMS) and neuromyelitis optica spectrum disorders (NMOSD).

12-03

2022

Five Articles from HealZen Therapeutics have been Selected for the 64th American Society of Hematology (ASH) Annual Meeting (New Orleans, USA)

ASH is one of the world's top-level international hematology conferences and attracts tens of thousands of experts and scholars engaged in clinical and basic research in the field of hematology from all over the world every year. ASH focuses on the latest developments and hot topics in the field, leading the direction of international development.

10-27

2022

HealZen's BTK Inhibitor HZ-A-018 Capsule Approved for Clinical Trials in China for ITP Treatment

HealZen Therapeutics announced that the self-developed chemical drug, BTK inhibitor HZ-A-018 capsule, has been approved by the National Medical Products Administration (NMPA) for clinical trials in China for the treatment of chronic/persistent adult primary immune thrombocytopenia (ITP).

06-10

2022

HealZen Therapeutics and Hisun Pharmaceutical Entered into Strategic Cooperation and Initiating the First Targeted Protein Degradation Drug Development

HealZen Therapeutics ( ‘HealZen’) and Zhejiang Hisun Pharmaceutical Co., Ltd. (‘Hisun’) have announced a strategic partnership agreement to collaborate on the development of new drugs from R&D to commercialization by leveraging their respective technologies, resources, and teams.